RUBICON
NSERubicon Research Limited (SMALL CAP)
Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,295.50
10.20 (0.79%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹21.34K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
N/A
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹570.75+127.0%
52W High₹1,370-5.4%
Current Price
₹1,295.50
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,036.40
Upper Circuit₹1,554.60
Reference Price
₹1,295.50
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹892.55
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹778.2
Trend: Price above all key MAs — strong uptrend
3-day momentum: +10.7% — strong upward pressure
Composite score 51.89 (BUY) with 86.1% confidence
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
86%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend
EMA20
1135.97
EMA50
1016.44
Price Action
MIXED
NEUTRAL
Higher Highs3
Higher Lows8
Lower Highs6
Lower Lows1
Support & Resistance Levels
Resistance (Above)
₹1370.00
Support (Below)
₹1014.55
₹940.15
₹918.00
₹816.76
₹757.00
Volume Analysis
TrendINCREASING
Change+1127.80%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹1282.55
3% Risk₹1256.63
5% Risk₹1230.72
7% Risk (Custom)
₹1204.81Technical Levels
1x ATR (Volatility)₹1218.10
2x ATR (Swing)₹1140.70
3x ATR (Trend)₹1063.30
Immediate Support₹1014.55
Moving Averages
EMA 9 (Short-term)₹1213.38
EMA 20 (Medium-term)₹1135.97
EMA 50 (Trend)₹1016.44
Financials
Financial data not available
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for RUBICON
View All
positive
Business Standard - Markets 12d ago
Rubicon Research jumps 15% to hit 52-week high on Q4 results, dividend news
Along with its quarterly results, the board recommended a dividend of ₹1.50 per equity share of face value ₹1 each, fully paid up, for the financial year ended March 31, 2026
DIVIDENDJMFINANCILRUBICONVALUEFinancial ServicesHealthcare
NEWS
neutral
Business Standard - Markets 12d ago
Alkali Metals Ltd leads gainers in 'B' group
NIIT Ltd, Lorenzini Apparels Ltd, Deep Polymers Ltd and Rubicon Research Ltd are among the other gainers in the BSE's 'B' group today, 01 June 2026.
ALKALIBSEDEEPINDSLALNIITLTDRUBICONSPALChemicalsConsumer Services
NEWS
positive
Business Standard - Markets 12d ago
Rubicon Research spurts after reporting strong Q4 performance
Rubicon Research surged 12.55% to Rs 1,130 after the company's consolidated net profit soared 100% to Rs 76.78 crore on 43.49% increase in revenue from operations to Rs 513.91 crore in Q4 FY26 over Q4 FY25.
RUBICONHealthcare